Brief: Daré Bioscience Announces Positive Topline Results From Dare-Vva1 Phase 1/2 Clinical Study

Dare Bioscience

14/11/2022 17:50

Nov 14 (Reuters) - Dare Bioscience Inc  DARE.O :
    * DARÉ BIOSCIENCE ANNOUNCES POSITIVE TOPLINE RESULTS FROM
DARE-VVA1 PHASE 1/2 CLINICAL STUDY
    * DARE BIOSCIENCE INC - CURRENTLY NO FDA-APPROVED PRODUCTS
LABELED
FOR VVA TREATMENT FOR PATIENTS WITH OR AT RISK OF RECURRENCE OF
HR+ BREAST CANCER
    * DARE BIOSCIENCE - DARE-VVA1 DEMONSTRATED IMPROVEMENT IN
VAGINAL
CYTOLOGY PARAMETERS AND BOTHERSOME SYMPTOMS OF VVA, SUPPORTING
ONGOING DEVELOPMENT

Source text for Eikon:  ID:nGNXvG8N7 
Further company coverage:  DARE.O